Evaluation of three commercially-available chikungunya virus immunoglobulin G immunoassays

ABSTRACT The emergence of chikungunya virus in the Americas means the affected population is at risk of developing severe, chronic, rheumatologic disease, even months after acute infection. Accurate diagnostic methods for past infections are essential for differential diagnosis and consequence manag...

Full description

Bibliographic Details
Main Authors: Pablo M. De Salazar, Anne Marie Valadere, Christin H. Goodman, Barbara W. Johnson
Format: Article in Journal/Newspaper
Language:English
Spanish
Portuguese
Published: Pan American Health Organization 2017
Subjects:
Virus chikungunya
juego de reactivos para diagnóstico
diagnostic
inmunoensayo
técnicas para inmunoenzimas
inmunoensayo de polarización fluorescente
Región del Caribe
Américas
Medicine
R
Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Arctic
Online Access:https://doaj.org/article/8e77f9c52eea478b88b70232934e32d8
Description
Summary:ABSTRACT The emergence of chikungunya virus in the Americas means the affected population is at risk of developing severe, chronic, rheumatologic disease, even months after acute infection. Accurate diagnostic methods for past infections are essential for differential diagnosis and consequence management. This study evaluated three commercially-available chikungunya Immunoglobulin G immunoassays by comparing them to an in-house Enzyme-Linked ImmunoSorbent Assay conducted by the Centers for Disease Control and Prevention (Atlanta, Georgia, United States). Results showed sensitivity and specificity values ranging from 92.8% – 100% and 81.8% – 90.9%, respectively, with a significant number of false-positives ranging from 12.5% – 22%. These findings demonstrate the importance of evaluating commercial kits, especially regarding emerging infectious diseases whose medium and long-term impact on the population is unclear.

Similar Items